🙈_老虎社区_美港股上老虎

2021-05-26

🙈

Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?<blockquote>这项研究对辉瑞的COVID疫苗销售来说会是坏消息吗？</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":136358918,"tweetId":"136358918","gmtCreate":1621995744534,"gmtModify":1634184852066,"author":{"id":3581978086195615,"idStr":"3581978086195615","authorId":3581978086195615,"authorIdStr":"3581978086195615","name":"KeppelTrader","avatar":"https://static.tigerbbs.com/b6a286c453e18361df44a005b4226cc8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>🙈</body></html>","htmlText":"<html><head></head><body>🙈</body></html>","text":"🙈","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/136358918","repostId":1191037526,"repostType":4,"repost":{"id":"1191037526","kind":"news","pubTimestamp":1621994290,"share":"https://www.laohunote.com/m/news/1191037526?lang=zh_CN&edition=full","pubTime":"2021-05-26 09:58","market":"us","language":"en","title":"Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?<blockquote>这项研究对辉瑞的COVID疫苗销售来说会是坏消息吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191037526","media":"Motley Fool","summary":"Pfizer(NYSE:PFE) stated earlier this month that it expects its COVID-19 vaccine will generate sales ","content":"Pfizer(NYSE:PFE)&nbsp;stated earlier this month that it expects its COVID-19 vaccine will generate sales of close to $26 billion this year. More revenue is on the way beyond 2021. For example, Pfizer and its partnerBioNTech(NASDAQ:BNTX)recently announced a new deal with the European Union tosupply up to 1.8 billion additional dosesthrough 2023.<blockquote>辉瑞（纽约证券交易所股票代码：PFE）本月早些时候表示，预计其 COVID-19 疫苗今年的销售额将接近 260 亿美元。2021 年后将有更多收入。例如，辉瑞及其合作伙伴生物技术（纳斯达克股票代码：BNTX）最近宣布与欧盟达成一项新协议，到 2023 年额外供应多达 18 亿剂疫苗。</blockquote> However, the dynamics of the COVID-19 vaccine market are constantly changing. Last week, researchers in Spain reported results from a clinical study that included Pfizer's COVID-19 vaccine. Could these results be bad news for future sales of Pfizer's vaccine?<blockquote>然而，新冠肺炎疫苗市场的动态在不断变化。上周，西班牙的研究人员报告了一项临床研究的结果，其中包括辉瑞的 COVID-19 疫苗。这些结果对辉瑞疫苗的未来销售会是坏消息吗？</blockquote> <img src=\"https://static.tigerbbs.com/5ae75aadcdda23603ea8f59dda16c30a\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> A mix-and-match milestone<blockquote>混搭里程碑</blockquote> Scientists have wondered what would happen if the initial dose of one COVID-19 vaccine was followed by a second dose from another vaccine. A few so-called \"mix-and-match\" clinical studies have been undertaken to find the answer. On May 18, the first results from one of those studies were announced.<blockquote>科学家们想知道，如果一种新冠肺炎疫苗的第一剂之后是另一种疫苗的第二剂，会发生什么。已经进行了一些所谓的“混搭”临床研究来寻找答案。5月18日，其中一项研究的首批结果公布。</blockquote> Researchers at the Carlos III Health Institute in Spain recruited participants for the CombiVacS clinical study who had received only a single dose ofAstraZeneca's(NASDAQ:AZN)vaccine within the previous eight weeks. Instead of administering the second dose of AstraZeneca's vaccine, the Spanish team gave the participants Pfizer's and BioNTech's COVID-19 vaccine instead.<blockquote>西班牙卡洛斯三世健康研究所的研究人员招募了仅接受单剂量CombiVacS临床研究的参与者阿斯利康’s（纳斯达克股票代码：AZN）疫苗在过去八周内。西班牙团队没有注射第二剂阿斯利康疫苗，而是给参与者注射了辉瑞和BioNTech的新冠肺炎疫苗。</blockquote> What happened? Participants receiving a first dose of the AstraZeneca vaccine followed by a second dose of the Pfizer vaccine experienced immune system responses that were \"greatly enhanced.\" The researchers reported that antibody levels for this group were at least 40 times higher than for individuals who only received a single dose of AstraZeneca's vaccine. These antibody levels were also higher than those reported for individuals who received two doses of the Pfizer vaccine.<blockquote>发生什么事了？接受第一剂阿斯利康疫苗，然后接受第二剂辉瑞疫苗的参与者经历了“大大增强”的免疫系统反应。研究人员报告说，这一群体的抗体水平至少比只接种一剂阿斯利康疫苗的个体高40倍。这些抗体水平也高于接受两剂辉瑞疫苗的个体报告的抗体水平。</blockquote> Side effects were similar to those observed in the past with the Pfizer vaccine. There were no adverse effects that required special medical attention or hospitalization. The most common side effects were headache, malaise, nausea, cough, and fever, most of which were mild cases.<blockquote>副作用与过去使用辉瑞疫苗观察到的副作用相似。没有需要特殊医疗护理或住院治疗的不良反应。最常见的副作用是头痛、不适、恶心、咳嗽和发热，其中大多数是轻度病例。</blockquote> Bad for Pfizer?<blockquote>对辉瑞不利？</blockquote> It's easy to see how these mix-and-match results might negatively impact the sales of Pfizer's vaccine. If a combination of one dose of the AstraZeneca vaccine with a second dose of the Pfizer vaccine is more effective than two doses of the Pfizer vaccine, governments could want to take this approach. In theory, that could slash Pfizer's sales in half.<blockquote>很容易看出这些混合搭配的结果可能会对辉瑞疫苗的销售产生负面影响。如果一剂阿斯利康疫苗与第二剂辉瑞疫苗的组合比两剂辉瑞疫苗更有效，政府可能希望采取这种方法。理论上，这可能会使辉瑞的销售额减半。</blockquote> But don't put the cart before the horse: The Spanish clinical study hasn't been peer-reviewed yet. Also, the study itself was relatively small -- only 673 people in total, with 443 receiving the mix-and-match doses and 232 only receiving the first AstraZeneca dose.<blockquote>但不要本末倒置：西班牙的临床研究尚未经过同行评审。此外，这项研究本身规模相对较小——总共只有 673 人，其中 443 人接受了混合匹配剂量，232 人只接受了第一剂阿斯利康剂量。</blockquote> The European Union isn't likely to want to go with a mix of AstraZeneca and Pfizer vaccines, however. The EU issuing AstraZenecaover allegedly failing to meet its supply commitments. This dispute played a major role in Pfizer and BioNTech winning a big supply deal that covers the next couple of years.<blockquote>然而，欧盟不太可能想混合使用阿斯利康和辉瑞疫苗。欧盟因涉嫌未能履行其供应承诺而对阿斯利康发出禁令。这场纠纷在辉瑞和 BioNTech 赢得未来几年的大型供应协议中发挥了重要作用。</blockquote> Even if the findings made by the Spanish researchers are eventually confirmed, it could still be too late to make much of a difference. There's a good chance that in future, only single-dose annual vaccinations will be required. If that's the case, any advantages offered by a two-dose regimen, including one combining AstraZeneca's and Pfizer's vaccines, could be irrelevant.<blockquote>即使西班牙研究人员的发现最终得到证实，也可能为时已晚，无法做出太大的改变。很有可能在未来，每年只需要单剂疫苗接种。如果是这样的话，两剂方案提供的任何优势，包括结合阿斯利康和辉瑞疫苗的方案，都可能无关紧要。</blockquote> What really matters<blockquote>真正重要的是什么</blockquote> Results from the mix-and-match studies probably won't present major problems for Pfizer (or for any of the other leading vaccine makers, for that matter). What really matters for the company is how frequently booster doses will be needed.<blockquote>混合匹配研究的结果可能不会给辉瑞（或任何其他领先的疫苗制造商）带来重大问题。对该公司来说，真正重要的是需要加强剂量的频率。</blockquote> The answer to that question probably won't be answered until sometime this fall. Meanwhile, investors appear to be discounting the likelihood that Pfizer will be able to count on huge recurring revenue for years to come: The bigpharma stocktrades at only around 12 times expected earnings. Should COVID-19 vaccines be needed at least once per year from here on out, Pfizer could be viewed, in retrospect, as a bargain at its current price.<blockquote>这个问题的答案可能要到今年秋天的某个时候才能得到答案。与此同时，投资者似乎忽视了辉瑞未来几年能够依靠巨额经常性收入的可能性：这家大型制药公司的股票交易价格仅为预期市盈率的 12 倍左右。如果从现在开始每年至少需要一次 COVID-19 疫苗，那么回想起来，辉瑞可能会被视为目前价格的便宜货。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?<blockquote>这项研究对辉瑞的COVID疫苗销售来说会是坏消息吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould This Study Be Bad News for Pfizer's COVID Vaccine Sales?<blockquote>这项研究对辉瑞的COVID疫苗销售来说会是坏消息吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-05-26 09:58\n\n</h4>\n</header>\n<article>\nPfizer(NYSE:PFE)&nbsp;stated earlier this month that it expects its COVID-19 vaccine will generate sales of close to $26 billion this year. More revenue is on the way beyond 2021. For example, Pfizer and its partnerBioNTech(NASDAQ:BNTX)recently announced a new deal with the European Union tosupply up to 1.8 billion additional dosesthrough 2023.<blockquote>辉瑞（纽约证券交易所股票代码：PFE）本月早些时候表示，预计其 COVID-19 疫苗今年的销售额将接近 260 亿美元。2021 年后将有更多收入。例如，辉瑞及其合作伙伴生物技术（纳斯达克股票代码：BNTX）最近宣布与欧盟达成一项新协议，到 2023 年额外供应多达 18 亿剂疫苗。</blockquote> However, the dynamics of the COVID-19 vaccine market are constantly changing. Last week, researchers in Spain reported results from a clinical study that included Pfizer's COVID-19 vaccine. Could these results be bad news for future sales of Pfizer's vaccine?<blockquote>然而，新冠肺炎疫苗市场的动态在不断变化。上周，西班牙的研究人员报告了一项临床研究的结果，其中包括辉瑞的 COVID-19 疫苗。这些结果对辉瑞疫苗的未来销售会是坏消息吗？</blockquote> <img src=\"https://static.tigerbbs.com/5ae75aadcdda23603ea8f59dda16c30a\" tg-width=\"700\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> A mix-and-match milestone<blockquote>混搭里程碑</blockquote> Scientists have wondered what would happen if the initial dose of one COVID-19 vaccine was followed by a second dose from another vaccine. A few so-called \"mix-and-match\" clinical studies have been undertaken to find the answer. On May 18, the first results from one of those studies were announced.<blockquote>科学家们想知道，如果一种新冠肺炎疫苗的第一剂之后是另一种疫苗的第二剂，会发生什么。已经进行了一些所谓的“混搭”临床研究来寻找答案。5月18日，其中一项研究的首批结果公布。</blockquote> Researchers at the Carlos III Health Institute in Spain recruited participants for the CombiVacS clinical study who had received only a single dose ofAstraZeneca's(NASDAQ:AZN)vaccine within the previous eight weeks. Instead of administering the second dose of AstraZeneca's vaccine, the Spanish team gave the participants Pfizer's and BioNTech's COVID-19 vaccine instead.<blockquote>西班牙卡洛斯三世健康研究所的研究人员招募了仅接受单剂量CombiVacS临床研究的参与者阿斯利康’s（纳斯达克股票代码：AZN）疫苗在过去八周内。西班牙团队没有注射第二剂阿斯利康疫苗，而是给参与者注射了辉瑞和BioNTech的新冠肺炎疫苗。</blockquote> What happened? Participants receiving a first dose of the AstraZeneca vaccine followed by a second dose of the Pfizer vaccine experienced immune system responses that were \"greatly enhanced.\" The researchers reported that antibody levels for this group were at least 40 times higher than for individuals who only received a single dose of AstraZeneca's vaccine. These antibody levels were also higher than those reported for individuals who received two doses of the Pfizer vaccine.<blockquote>发生什么事了？接受第一剂阿斯利康疫苗，然后接受第二剂辉瑞疫苗的参与者经历了“大大增强”的免疫系统反应。研究人员报告说，这一群体的抗体水平至少比只接种一剂阿斯利康疫苗的个体高40倍。这些抗体水平也高于接受两剂辉瑞疫苗的个体报告的抗体水平。</blockquote> Side effects were similar to those observed in the past with the Pfizer vaccine. There were no adverse effects that required special medical attention or hospitalization. The most common side effects were headache, malaise, nausea, cough, and fever, most of which were mild cases.<blockquote>副作用与过去使用辉瑞疫苗观察到的副作用相似。没有需要特殊医疗护理或住院治疗的不良反应。最常见的副作用是头痛、不适、恶心、咳嗽和发热，其中大多数是轻度病例。</blockquote> Bad for Pfizer?<blockquote>对辉瑞不利？</blockquote> It's easy to see how these mix-and-match results might negatively impact the sales of Pfizer's vaccine. If a combination of one dose of the AstraZeneca vaccine with a second dose of the Pfizer vaccine is more effective than two doses of the Pfizer vaccine, governments could want to take this approach. In theory, that could slash Pfizer's sales in half.<blockquote>很容易看出这些混合搭配的结果可能会对辉瑞疫苗的销售产生负面影响。如果一剂阿斯利康疫苗与第二剂辉瑞疫苗的组合比两剂辉瑞疫苗更有效，政府可能希望采取这种方法。理论上，这可能会使辉瑞的销售额减半。</blockquote> But don't put the cart before the horse: The Spanish clinical study hasn't been peer-reviewed yet. Also, the study itself was relatively small -- only 673 people in total, with 443 receiving the mix-and-match doses and 232 only receiving the first AstraZeneca dose.<blockquote>但不要本末倒置：西班牙的临床研究尚未经过同行评审。此外，这项研究本身规模相对较小——总共只有 673 人，其中 443 人接受了混合匹配剂量，232 人只接受了第一剂阿斯利康剂量。</blockquote> The European Union isn't likely to want to go with a mix of AstraZeneca and Pfizer vaccines, however. The EU issuing AstraZenecaover allegedly failing to meet its supply commitments. This dispute played a major role in Pfizer and BioNTech winning a big supply deal that covers the next couple of years.<blockquote>然而，欧盟不太可能想混合使用阿斯利康和辉瑞疫苗。欧盟因涉嫌未能履行其供应承诺而对阿斯利康发出禁令。这场纠纷在辉瑞和 BioNTech 赢得未来几年的大型供应协议中发挥了重要作用。</blockquote> Even if the findings made by the Spanish researchers are eventually confirmed, it could still be too late to make much of a difference. There's a good chance that in future, only single-dose annual vaccinations will be required. If that's the case, any advantages offered by a two-dose regimen, including one combining AstraZeneca's and Pfizer's vaccines, could be irrelevant.<blockquote>即使西班牙研究人员的发现最终得到证实，也可能为时已晚，无法做出太大的改变。很有可能在未来，每年只需要单剂疫苗接种。如果是这样的话，两剂方案提供的任何优势，包括结合阿斯利康和辉瑞疫苗的方案，都可能无关紧要。</blockquote> What really matters<blockquote>真正重要的是什么</blockquote> Results from the mix-and-match studies probably won't present major problems for Pfizer (or for any of the other leading vaccine makers, for that matter). What really matters for the company is how frequently booster doses will be needed.<blockquote>混合匹配研究的结果可能不会给辉瑞（或任何其他领先的疫苗制造商）带来重大问题。对该公司来说，真正重要的是需要加强剂量的频率。</blockquote> The answer to that question probably won't be answered until sometime this fall. Meanwhile, investors appear to be discounting the likelihood that Pfizer will be able to count on huge recurring revenue for years to come: The bigpharma stocktrades at only around 12 times expected earnings. Should COVID-19 vaccines be needed at least once per year from here on out, Pfizer could be viewed, in retrospect, as a bargain at its current price.<blockquote>这个问题的答案可能要到今年秋天的某个时候才能得到答案。与此同时，投资者似乎忽视了辉瑞未来几年能够依靠巨额经常性收入的可能性：这家大型制药公司的股票交易价格仅为预期市盈率的 12 倍左右。如果从现在开始每年至少需要一次 COVID-19 疫苗，那么回想起来，辉瑞可能会被视为目前价格的便宜货。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/05/25/could-this-study-be-bad-news-pfizers-covid-vaccine/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/05/25/could-this-study-be-bad-news-pfizers-covid-vaccine/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191037526","content_text":"Pfizer(NYSE:PFE) stated earlier this month that it expects its COVID-19 vaccine will generate sales of close to $26 billion this year. More revenue is on the way beyond 2021. For example, Pfizer and its partnerBioNTech(NASDAQ:BNTX)recently announced a new deal with the European Union tosupply up to 1.8 billion additional dosesthrough 2023.\nHowever, the dynamics of the COVID-19 vaccine market are constantly changing. Last week, researchers in Spain reported results from a clinical study that included Pfizer's COVID-19 vaccine. Could these results be bad news for future sales of Pfizer's vaccine?\n\nIMAGE SOURCE: GETTY IMAGES.\nA mix-and-match milestone\nScientists have wondered what would happen if the initial dose of one COVID-19 vaccine was followed by a second dose from another vaccine. A few so-called \"mix-and-match\" clinical studies have been undertaken to find the answer. On May 18, the first results from one of those studies were announced.\nResearchers at the Carlos III Health Institute in Spain recruited participants for the CombiVacS clinical study who had received only a single dose ofAstraZeneca's(NASDAQ:AZN)vaccine within the previous eight weeks. Instead of administering the second dose of AstraZeneca's vaccine, the Spanish team gave the participants Pfizer's and BioNTech's COVID-19 vaccine instead.\nWhat happened? Participants receiving a first dose of the AstraZeneca vaccine followed by a second dose of the Pfizer vaccine experienced immune system responses that were \"greatly enhanced.\" The researchers reported that antibody levels for this group were at least 40 times higher than for individuals who only received a single dose of AstraZeneca's vaccine. These antibody levels were also higher than those reported for individuals who received two doses of the Pfizer vaccine.\nSide effects were similar to those observed in the past with the Pfizer vaccine. There were no adverse effects that required special medical attention or hospitalization. The most common side effects were headache, malaise, nausea, cough, and fever, most of which were mild cases.\nBad for Pfizer?\nIt's easy to see how these mix-and-match results might negatively impact the sales of Pfizer's vaccine. If a combination of one dose of the AstraZeneca vaccine with a second dose of the Pfizer vaccine is more effective than two doses of the Pfizer vaccine, governments could want to take this approach. In theory, that could slash Pfizer's sales in half.\nBut don't put the cart before the horse: The Spanish clinical study hasn't been peer-reviewed yet. Also, the study itself was relatively small -- only 673 people in total, with 443 receiving the mix-and-match doses and 232 only receiving the first AstraZeneca dose.\nThe European Union isn't likely to want to go with a mix of AstraZeneca and Pfizer vaccines, however. The EU issuing AstraZenecaover allegedly failing to meet its supply commitments. This dispute played a major role in Pfizer and BioNTech winning a big supply deal that covers the next couple of years.\nEven if the findings made by the Spanish researchers are eventually confirmed, it could still be too late to make much of a difference. There's a good chance that in future, only single-dose annual vaccinations will be required. If that's the case, any advantages offered by a two-dose regimen, including one combining AstraZeneca's and Pfizer's vaccines, could be irrelevant.\nWhat really matters\nResults from the mix-and-match studies probably won't present major problems for Pfizer (or for any of the other leading vaccine makers, for that matter). What really matters for the company is how frequently booster doses will be needed.\nThe answer to that question probably won't be answered until sometime this fall. Meanwhile, investors appear to be discounting the likelihood that Pfizer will be able to count on huge recurring revenue for years to come: The bigpharma stocktrades at only around 12 times expected earnings. Should COVID-19 vaccines be needed at least once per year from here on out, Pfizer could be viewed, in retrospect, as a bargain at its current price.","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":510,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/136358918"}